New study aims to predict who will benefit from liver cancer immunotherapy

NCT ID NCT07623265

Recruiting now Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid giving ineffective treatments and their side effects to those who won't benefit. About 300 adults with suspected or confirmed liver cancer will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

AZ Delta
RECRUITING

Roeselare, Belgium
AZ Groeninge
RECRUITING

Kortrijk, Belgium
Jessa ziekenhuis
RECRUITING

Hasselt, Belgium
UZA
RECRUITING

Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.